Nevertheless, the clinical efficacy of PD-1/PD-L1 inhibitor monotherapy in prostate cancer patients persists at suboptimal levels, which may be partially explained by the characteristically low PD-L1 expression levels observed in prostate cancer. This evidence concerns the gene CD274 and prostate cancer.